BLAINJECTIONINJECTABLE
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications (2)
Clinical Trials (5)
Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults
Started Apr 2025
180 enrolled
Healthy Volunteer
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Started Dec 2021
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
Started Oct 2019
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer
Started Aug 2018
90 enrolled
HER2-positive Breast CancerOperable Breast Cancer
Patient Preference for Pegfilgrastim (Neulasta®) Application Forms
Started Jun 2018
404 enrolled
Non Hodgkin LymphomaBreast Cancer